New York, NY – May 9, 2019 – Sichenzia Ross Ference LLP announced today that the firm represented AIT Therapeutics, Inc. (NASDAQ: AITB), in the Company’s uplisting to the NASDAQ Capital Market. The Sichenzia Ross Ference LLP team was led by founding partner Gregory Sichenzia and partner Avital Perlman. The uplisting is effective for trading on May 7, 2019, and AITB’s common stock will trade under its existing stock symbol, “AITB.”
“We applaud AITB on the achievement of this important milestone, one that positions the Company to capitalize on its market objectives as it continues to develop its inhaled nitric oxide treatment for patients with respiratory conditions,” said Gregory Sichenzia.
